Urinary tract infection, inflammation, and cognition in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study

被引:0
|
作者
Thomas, Joshua [1 ]
McEvoy, Joseph P. [2 ]
Miller, Brian J. [2 ]
机构
[1] Augusta Univ, Dept Psychiat & Hlth Behav, Med Coll Georgia, Augusta, GA 30912 USA
[2] Augusta Univ, Dept Psychiat & Hlth Behav, 997 St Sebastian Way, Augusta, GA 30912 USA
关键词
TOXOPLASMA-GONDII; BIPOLAR DISORDER; VIRAL ANTIBODIES; SCHIZOPHRENIA; RISK; INDIVIDUALS; ASSOCIATION; MORTALITY; METAANALYSIS; CHILDHOOD;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
BACKGROUND: Schizophrenia is associated with an increased prevalence of infections throughout the life span. Previous studies have found an association between urinary tract infection (UTI) and acute psychosis. We investigated the prevalence and correlates of UTI in a large cohort of patients with schizophrenia. METHODS: We estimated the prevalence of UTI at the baseline visit of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. We then investigated associations between UTI and inflammatory markers, psychopathology, and cognition, controlling for potential confounding factors. RESULTS: The prevalence of probable UTI at baseline in the CATIE trial was 1.2% (n = 13 of 1,061 participants). Compared with participants with a normal urinalysis (n = 387), after controlling for potential confounders, UTI was a significant predictor of greater impairments (approximately 1 standard deviation difference) in the cognition composite score (beta = -0.153, P = .002), and poorer working memory (beta = -0.190, P < .001). There were no differences in psychopathology scores between participants with probable UTI and those with a normal urinalysis. CONCLUSIONS: Urinary tract infections in patients with schizophrenia may have an impact on cognition. Findings provide additional evidence regarding infectious disease comorbidity, which may be clinically relevant in the treatment of patients with schizophrenia.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 50 条
  • [1] Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study
    Miller, Brian J.
    Buckley, Peter F.
    McEvoy, Joseph P.
    SCHIZOPHRENIA RESEARCH, 2018, 195 : 275 - 282
  • [2] Insomnia and inflammation in phase 1 of the clinical antipsychotic trials of intervention effectiveness study
    Miller, Brian J.
    V. McCall, William
    McEvoy, Joseph P.
    Lu, Xin-Yun
    PSYCHIATRY RESEARCH, 2021, 305
  • [3] Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study
    Mori, Neil
    McEvoy, Joseph P.
    Miller, Brian J.
    SCHIZOPHRENIA RESEARCH, 2015, 169 (1-3) : 30 - 35
  • [4] Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study
    Meyer, Jonathan M.
    McEvoy, Joseph P.
    Davis, Vicki G.
    Goff, Donald C.
    Nasrallah, Henry A.
    Davis, Sonia M.
    Hsiao, John K.
    Swartz, Marvin S.
    Stroup, T. Scott
    Lieberman, Jeffrey A.
    BIOLOGICAL PSYCHIATRY, 2009, 66 (11) : 1013 - 1022
  • [5] Clinical Antipsychotic Trials of Intervention Effectiveness Study A Pragmatic Trial?
    Manjunatha, Narayana
    Saddichha, Sahoo
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2009, 29 (04) : 410 - 411
  • [6] Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study
    Kelly, Conor W.
    McEvoy, Joseph P.
    Miller, Brian J.
    SCHIZOPHRENIA RESEARCH, 2019, 209 : 193 - 197
  • [7] Prevalence of Celiac Disease and Gluten Sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population
    Cascella, Nicola G.
    Kryszak, Debra
    Bhatti, Bushra
    Gregory, Patricia
    Kelly, Deanna L.
    Mc Evoy, Joseph P.
    Fasano, Alessio
    Eaton, William W.
    SCHIZOPHRENIA BULLETIN, 2011, 37 (01) : 94 - 100
  • [8] Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
    Melkote, Rama
    Singh, Arun
    Vermeulen, An
    Remmerie, Bart
    Savitz, Adam
    SCHIZOPHRENIA RESEARCH, 2018, 201 : 324 - 328
  • [9] The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study
    Ostergaard, Soren D.
    Foldager, Leslie
    Mors, Ole
    Bech, Per
    Correll, Christoph U.
    SCHIZOPHRENIA BULLETIN, 2018, 44 (02) : 453 - 462
  • [10] Evaluation of "subject advocate" procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study
    Stroup, TS
    Appelbaum, PS
    SCHIZOPHRENIA BULLETIN, 2006, 32 (01) : 147 - 152